Xuan Xu

Prof. Xuan Xu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
XXXuan Xu
Xuan Xu
JWJiaqi Wang
Jiaqi Wang
TCTong Chen
Tong Chen
SWShuaibin Wang
Shuaibin Wang
FWFei Wang
Fei Wang
YSYin Shen
Yin Shen
Introduction: Alzheimer’s disease (AD) and glioblastoma (GBM) are severe neurological disorders that pose significant global healthcare challenges. Despite extensive research, the molecular mechanisms, particularly those involving mitochondrial dysfunction, remain poorly understood. A major limitation in current studies is the lack of cell-specific markers that effectively represent mitochondrial dynamics in AD and GBM.Methods: In this study, we analyzed single-cell transcriptomic data using 10 machine learning algorithms to identify mitochondria-associated cell-specific markers. We validated these markers through the integration of gene expression and methylation data across diverse cell types. Our dataset comprised single-nucleus RNA sequencing (snRNA-seq) from AD patients, single-cell RNA sequencing (scRNA-seq) from GBM patients, and additional DNA methylation and transcriptomic data from the ROSMAP, ADNI, TCGA, and CGGA cohorts.Results: Our analysis identified four significant cross-disease mitochondrial markers: EFHD1, SASH1, FAM110B, and SLC25A18. These markers showed both shared and unique expression profiles in AD and GBM, suggesting a common mitochondrial mechanism contributing to both diseases. Additionally, oligodendrocytes and their interactions with astrocytes were implicated in disease progression, particularly through the APP signaling pathway. Key hub genes, such as HS6ST3 and TUBB2B, were identified across different cellular subpopulations, highlighting a cell-specific co-expression network linked to mitochondrial function.

27 October 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
XXXuan Xu
Xuan Xu
SFSha‐Sha Fan
Sha‐Sha Fan
JLJiang Li
Jiang Li
HWHao Wu
Hao Wu
JHJunwen He
Junwen He
YSYin Shen
Yin Shen
Aims: Alzheimer's disease (AD) is a devastating neurodegenerative disorder where mitochondrial dysfunction is increasingly recognized as pivotal, yet its comprehensive molecular underpinnings remain incompletely understood. This study aimed to systematically identify and validate mitochondria‐related biomarkers associated with AD risk and brain resilience, thus elucidating the molecular mechanisms underpinning mitochondrial dysfunction in AD. Methods: We innovatively integrated a multi‐omics approach, encompassing genomics, DNA methylation, RNA‐sequencing, and miRNA profiles from the ROSMAP and ADNI cohorts (sample sizes ranging from 638 to 2090 per omic layer). Additionally, we applied 10 distinct machine learning methods to robustly identify and validate critical mitochondrial biomarkers relevant to AD progression. Subsequent validation was performed using a two‐tiered approach: an in vivo AD mouse model to establish phenotypic relevance and an in vitro H 2 O 2 ‐induced oxidative stress model in HT22 cells to provide direct mechanistic validation. Results: Our computational analyses identified key biomarkers such as hsa‐miR‐129‐5p and SLC6A12 as pivotal regulators and highlighted the importance of the tricarboxylic acid (TCA) cycle. Experimentally, our AD mouse model exhibited significant cognitive deficits and brain remodeling, linked to a specific transcriptomic signature. Our in vitro model functionally recapitulated mitochondrial dysfunction and oxidative stress. Crucially, a cross‐model analysis revealed a core signature of seven genes (including APOE , CDKN1A , and CLOCK ) consistently dysregulated in both the cognitively impaired mouse brain and in neuronal cells subjected to direct oxidative insult. This provides powerful functional evidence linking our computationally derived targets, such as mitochondrial‐epistatic genes ( CLOCK ), to AD‐relevant pathology. Conclusion: These functionally validated findings provide deeper insights into the complex mitochondrial regulatory mechanisms involved in AD pathogenesis, offering robust biomarkers and novel potential avenues for developing targeted therapeutic strategies to address this challenging neurodegenerative disease.

Verified
Journal Article
Open access
PDF file
YDYanan Du
Yanan Du
XXXiao-Yong Xia
Xiao-Yong Xia
ZNZhu Ni
Zhu Ni
SFSha-Sha Fan
Sha-Sha Fan
JHJunwen He
Junwen He
XXXuan Xu
Xuan Xu
To resolve the ambiguous causal relationship between sleep disturbances and neurodegenerative diseases such as Alzheimer’s disease (AD), we conducted a multi-stage genetic and multi-omics investigation. Our large-scale bidirectional Mendelian randomization analysis identified a robust, asymmetrical pattern of genetic association, providing strong genetic evidence suggesting that liability for neurocognitive decline and AD is associated with sleep disturbances, with substantially weaker evidence for the reverse direction. To identify the underlying molecular drivers, a multi-omics Summary-data-based MR (SMR) analysis prioritized high-confidence causal genes, including YWHAZ, NT5C2, COX6B1, and CDK10. The predictive power of this gene signature was confirmed using machine learning models (ROC-AUC > 0.8), while functional validation through bulk and single-cell transcriptomics uncovered profound, cell-type-specific dysregulation in the AD brain, most notably opposing expression patterns between neurons and glial cells (e.g., YWHAZ was upregulated in excitatory neurons but downregulated in glia). Functional enrichment and network analyses implicated two core pathways—nucleotide metabolism centered on NT5C2 and synaptic function involving YWHAZ—and our investigation culminated in the identification of a promising therapeutic interaction, with molecular docking validating high-affinity binding between Ecdysterone and COX6B1 (docking score = −5.73 kcal/mol). Collectively, our findings strengthen the evidence that sleep disruption as a likely consequence of neurodegenerative processes and prioritize a set of validated, cell-type-specific gene targets within critical pathways, offering promising new avenues for therapeutic development.

27 January 2026 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
ZNZhu Ni
Zhu Ni
XXXiao-Yong Xia
Xiao-Yong Xia
NCNa Cheng
Na Cheng
YBYu Bo
Yu Bo
XXXuan Xu
Xuan Xu
Background: Metabolic disorders and neurocognitive diseases frequently co-occur, yet the specific mechanisms driving this comorbidity remain elusive. While epidemiological associations are well-documented, the causal links between these conditions are complex and incompletely understood, necessitating a systems-level investigation into their shared biological architecture. Methods: This study integrates large-scale human genetics with experimental in vivo transcriptomics and computational chemistry to elucidate these shared pathways. Specifically, an AD-like murine model was used to experimentally prioritize a core network of 13 dysregulated genes within a pathologically relevant context. Results: Network-informed Mendelian randomization identified bidirectional causalities, including a 14% elevated dementia risk from type 2 diabetes and protective effects of obesity against parental Alzheimer’s disease (AD). The study identified a signature encompassing key lipid metabolism hubs APOE, CLU , and LDLR . This signature serves as a critical biological filter, anchoring human genetic associations by providing direct evidence of their dysregulation in a neurodegenerative environment. Subsequent chemical enrichment and molecular docking analyses indicated that these experimentally-prioritized targets are engaged by both therapeutic agents (e.g., valproic acid) and environmental toxins (e.g., benzo[a]pyrene). Conclusion: This multi-modal investigation provides a robust framework that converges on a high-confidence, 13-gene signature of lipid dysregulation as a central mechanistic interface, offering a powerful set of prioritized targets for future functional validation and therapeutic development at the metabolic-neurocognitive nexus.

14 March 2025 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
FWFei Wang
Fei Wang
JWJiaqi Wang
Jiaqi Wang
TCTong Chen
Tong Chen
SWShuaibin Wang
Shuaibin Wang
XMXiangYu Meng
XiangYu Meng
XXXuan Xu
Xuan Xu

5 June 2025 in Current Urology
Verified
Journal Article
Open access
MSMingjun Shi
Mingjun Shi
XMXiang-Yu Meng
Xiang-Yu Meng
XXXuan Xu
Xuan Xu
QWQiaoli Wang
Qiaoli Wang
Background: Although genetic variants associated with bladder cancer (BCa) risk have been identified through hypothesis-driven and genome-wide association studies, a systematic understanding of BCa genetic susceptibility at the gene and pathway levels remains to be achieved. Materials and methods: In this 2-stage functional genomics study, we used 5 independent tools for genome-wide gene mapping and ranking based on BCa genome-wide association studies summary statistics, followed by a meta-analysis of gene-level significance p values, to obtain a consensus gene ranking in terms of association with BCa. Subsequently, we performed preranked gene-set enrichment analysis to identify the functional pathways involved in BCa genetic susceptibility. Joint analysis with gene-set enrichment analysis, based on somatic alteration frequency, was performed to explore the pathway-level relationships between genetic susceptibility and somatic alterations in BCa. Results: Other than the well-known BCa genes (such as FGFR3, MYC, TERT, CCNE1, and TP63), we additionally prioritized a set of novel genes likely to be genetically implicated in BCa development, including SETD2, a possible tumor suppressor gene involved in chromatin remodeling. We further demonstrated convergence between genetic associations and somatic alterations at both the gene (eg, FGFR3 and TERT) and pathway levels (eg, cell cycle and chromatin modification), as well as functional ontologies specifically implicated in germline predisposition to BCa (eg, CD8/TCR signaling, immune checkpoints, and cytokine signaling). Conclusions: We identified several novel genes associated with BCa and demonstrated that genetic variants contribute to the development of BCa by affecting antitumor immunity, response to toxic exposure, and RNA and protein homeostasis and synergizing with somatic alterations in various cancer-related pathways.